August 16, 2025

Telmisartan, an anti-hypertensive drug, impedes JEV infection, possibly via the AT1/PPARγ axis.

View Full Paper

Ask AI

Bookmark

Telmisartan significantly reduced JEV titer, RNA, and protein in vitro and in vivo, indicating its anti-JEV efficacy.
The IC50 for telmisartan was found to be 24.68 µM, with a selectivity index greater than 14.18, highlighting its potential therapeutic value.
Observational analysis confirmed that treatment with telmisartan reversed inflammatory marker levels during JEV infection, suggesting an immunomodulatory mechanism.
Validation in a mouse model showed promising results with reduced disease scores and histological changes after telmisartan treatment.

Authors

Discussion

No takes yet. Share an insight, caveat, or question.

Observational analysis shows telmisartan reduces JEV levels in vitro and a mouse model, suggesting immunomodulatory effects via the AT1/PPARγ axis.

Datey et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Observational analysis shows telmisartan reduces JEV levels in vitro and a mouse model, suggesting immunomodulatory effects via the AT1/PPARγ axis.